Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
25 June 2015Website:
http://www.astriatx.comNext earnings report:
07 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 21 Jun 2024 20:16:22 GMTDividend
Analysts recommendations
Institutional Ownership
ATXS Latest News
Astria Therapeutics, Inc. (NASDAQ:ATXS ) Q3 2023 Earnings Conference Call November 13, 2023 8:30 AM ET Company Participants Elizabeth Higgins - Investor Relations Jill Milne - Co Founder, CEO, President & Director Noah Clauser - CFO & Treasurer Christopher Morabito - Chief Medical Officer Andrea Matthews - Chief Business Officer Andrew Komjathy - Chief Commercial Officer Conference Call Participants Eun Yang - Jefferies Sam Slutsky - LifeSci Capital Hartaj Singh - Oppenheimer Farhana Sakloth - Ladenburg Joe Pantginis - H.C. Wainwright Operator Good morning and welcome to the Astria Therapeutics Quarter Three 2023 Corporate Update.
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will share new STAR-0215 data in a poster presentation at the upcoming American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting in Anaheim, California on November 11, 2023 at 12:35pm PST. Dr. William Lumry, M.D., Clinical Professor of Internal Medicine at the Unive.
Astria Therapeutics has inked a worldwide exclusive license agreement with Ichnos Sciences for an OX40 portfolio targeting the potential treatment of atopic dermatitis (AD) and other allergic and immunological diseases. The focus of the collaboration centers on the development of the lead candidate, STAR-0310, a monoclonal antibody OX40 antagonist utilizing YTE half-life extension technology.
Astria (ATXS) gets FDA's fast track tag for its lead product candidate, STAR-0215, which is currently being evaluated in an early-mid-stage study to treat hereditary angioedema. The stock rises 5%.
Astria: Biotech To Watch With Proof Of Concept Established For HAE.
What type of business is Astria Therapeutics?
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
What sector is Astria Therapeutics in?
Astria Therapeutics is in the Healthcare sector
What industry is Astria Therapeutics in?
Astria Therapeutics is in the Biotechnology industry
What country is Astria Therapeutics from?
Astria Therapeutics is headquartered in United States
When did Astria Therapeutics go public?
Astria Therapeutics initial public offering (IPO) was on 25 June 2015
What is Astria Therapeutics website?
https://www.astriatx.com
Is Astria Therapeutics in the S&P 500?
No, Astria Therapeutics is not included in the S&P 500 index
Is Astria Therapeutics in the NASDAQ 100?
No, Astria Therapeutics is not included in the NASDAQ 100 index
Is Astria Therapeutics in the Dow Jones?
No, Astria Therapeutics is not included in the Dow Jones index
When does Astria Therapeutics report earnings?
The next expected earnings date for Astria Therapeutics is 07 August 2024